Objective To determine the value of [F-18]PBR06-PET for assessment of microglial activation in the cerebral gray matter in patients with MS.
There has been increasing recognition of gray matter pathology in MS since the seminal histopathologic description of gray matter plaques by Brownell et al. in 1962. 1,2 Microglial activation and neuronal loss have been demonstrated in gray matter MS lesions and normal-appearing gray matter. 1 Brain atrophy has been associated with disease progression, 3 and regional gray matter loss has been associated with specific clinical impairment. 4 However, the mechanism of brain atrophy in MS is not clear. There is a need to better understand the role of gray matter microglial activation in disease pathogenesis.
[F-18]PBR06 [N-(2,5-dimethoxybenzyl)-2-(18)F-fluoro-N-(2-phenoxyphenyl)acetamide] is a second-generation PET radioligand, targeting the 18-kDa-translocator protein (TSPO), which is overexpressed on activated microglia/ macrophages. 5 The longer physical half-life of F-18 (110 minutes) as compared to C-11 (20 minutes, used to label conventional TSPO ligands such as [C-11]PK11195) enables improved image quality, increased signal-to-noise ratio, and higher clinical feasibility. 6 Strong correlations of [F-18] PBR06-binding with both CD68 expression and TSPOantibody reactivity have been demonstrated in multiple disease models. 7, 8 [F-18]PBR06 has been studied in healthy human volunteers but not in MS, except for our recent study on white matter microglial activation in MS. 9 The aims of this pilot study were to assess differences in microglial activity in the cortical and subcortical gray matter regions between patients with MS and healthy controls (HCs), and between patients with relapsing-remitting (RR) and secondary progressive (SP) MS, and to identify any association of microglial activation with brain atrophy and physical disability using [F-18] PBR06 PET.
Methods
Participants Eighteen MS and 7 HC participants were initially enrolled. Two MS and 2 HC participants were low-affinity binders and were excluded from the study (see the Genotyping section below). Four additional MS participants subsequently lost interest or were lost to follow-up after initial screening. Ultimately, 12 patients with MS (7 RR and 5 SP; 8 women [67%]) and 5 HC participants (3 women, 60%) completed the study. Participant characteristics are summarized in table 1 and detailed for each participant in table 2. Clinical course (RR or SP) was initially determined by the treating neurologists and documented in the patient's chart.
The clinical course was subsequently verified by TS by chart review, and determination of SPMS was based on the 2013 International Advisory Committee on Clinical Trials of MS criteria. 10 The inclusion criteria required patients with SP to have demonstrated an increase in the Expanded Disability Status Scale (EDSS) score by 1.0 or 0.5, if the baseline EDSS score was <5 or ≥5.5, respectively, in the last 1 year. Patients with RR were included if there was a history of a clinical relapse in the last 1 year or if there was evidence of a new or enlarging T2 bright lesion on MRI or a gadolinium-enhancing lesion on T1-weighted MRI. Patients were excluded if they received corticosteroids in the last 1 month before PET scanning. The median time interval between formal clinical assessment and PET scanning was 5.1 (range 1.1-25.6) weeks. There was no history of relapses or clinical deterioration between the clinical visits immediately before and after the PET scanning.
Standard protocol approvals, registrations, and patient consents
The study is registered on clinicaltrials.gov with the clinical trial identifier number, NCT02649985. The study was approved by the Institutional Review Board and Radioactive Drug Research Committee at Brigham and Women's Hospital; written informed consent was obtained from all participants.
Genotyping
Blood samples drawn on the initial screening visit were genotyped for DNA polymorphism of the TSPO gene on chromosome 22q13.2, using a TaqMan assay. High-affinity and medium-affinity binders were included in the study, whereas low-affinity binders (4 participants, including 2 MS and 2 HC) were excluded. Among the 12 included patients with MS, 7 (58%) were high-affinity and 5 were medium-affinity binders, and among the HCs, 2 (40%) were high-affinity and 3 were medium-affinity binders (table 2) . There were no statistically significant differences in the TSPO-binding affinity distribution between the 2 groups (table 1) .
Production of radiopharmaceuticals [F-18]PBR06 was produced in the Nuclear Medicine/ Biomedical Imaging Research Core facility at our hospital according to standardized procedures. The product was purified by high-pressure liquid chromatography and sterilized by a 0.22-μm membrane filter. The final product was dispensed in an isotonic solution that was sterile and pyrogenfree for IV administration. The radiochemical purity (RCP) of radiopharmaceuticals was determined using high-pressure Glossary AAL = automated anatomic labeling; BPV = brain parenchymal volume; C-SUVR = total cortical gray standardized uptake value ratio; EDSS = Expanded Disability Status Scale; HC = healthy control; RCP = radiochemical purity; ROI = region of interest; RR = relapsing-remitting; SC-SUVR = total subcortical gray matter standardized uptake value ratio; SP = secondary progressive; SUVR = standardized uptake value ratio; T25FW = timed 25-foot walk; TSPO = translocator protein.
liquid chromatography. The organic solvents were determined using gas chromatography. The RCP of the radiopharmaceuticals was >95%.
MRI acquisition and analysis
All participants underwent MRI on the same scanner (Siemens 3T Skyra, Erlangen, Germany) using the same high-resolution acquisition protocol as previously described. [11] [12] [13] This included a 2D T1-weighted spin-echo axial series (the repetition time = 611-943 ms, and echo time = 7.9 ms, voxel size = 0.43 × 0.43 × 3 mm) and a 3D magnetization-prepared rapid gradient-echo series (voxel size 1 mm 3 ). The latter images were applied to a fully automated algorithm to derive normalized whole brain parenchymal volume (BPV) (SIENAX, v. 5.0; Analysis Group, fsl.fmrib.ox.ac.uk), using our previously described method.
14 PET acquisition and analysis [F-18]PBR06 was injected as a bolus injection for PET scanning using an IV catheter into the radial antecubital or other arm or hand vein; images were acquired in a list mode acquisition mode using a high-resolution PET/CT scanner (GE Discovery ECAT, Waukesha, WI).
For each participant, using the PNEURO 3.8 platform (PMOD Technologies, Zurich, Switzerland; pmod.com), summed [F-18] PBR06 PET images obtained between 60 and 90 minutes after tracer injection were coregistered to MRI, and segmentation of images into brain regions was based on the automated anatomical labeling (AAL) template within the PNEURO utilities suite. 15 Two regions of interest (ROIs) were derived after collapsing the supratentorial AAL template output: (1) a supratentorial cortical region of interest representing the union of 41 regions in each hemisphere, including the amygdala; (2) a subcortical gray matter ROI representing the union of the thalamus, caudate, putamen, and globus Abbreviations: EDSS = Expanded Disability Status Scale; HC = healthy control; T25FW = timed 25-foot walk; TSPO = translocator protein.
Data are mean ± SD, unless otherwise indicated. Abbreviations: Disease duration is time from the onset of first symptoms; DMT = disease-modifying treatment; EDSS = Expanded Disability Status Scale; RR = relapsing-remitting; SP = secondary progressive; TSPO = translocator protein; T25FW = timed 25-foot walk.
pallidus. To account for interparticipant differences, a total cortical gray matter and a total subcortical gray matter standardized uptake value ratio (SUVR) (C-SUVR and SC-SUVR, respectively) were calculated for each participant based on normalization of the individual region's SUV 6 Contrast-effect images were then progressed into group-level models. Parametric images were generated to demonstrate the age-and sex-adjusted correlations of thalamic PET uptake with the EDSS score, timed 25-foot walk (T25FW), and BPV in the MS group. All image analyses were performed blinded to study group and clinical scores.
Statistical analysis
For the primary analysis, the exact Wilcoxon-Mann-Whitney test was used to assess the statistical significance of mean differences in SUVRs. For age-adjusted comparisons between SPMS vs RRMS and HC groups, analysis of covariance was used to compare groups while including age in the model. To assess associations, Spearman correlation coefficient r's were calculated. This pilot study was exploratory in nature with a small sample size that is not based on formal sample size calculations, and results should be considered hypothesis generating. Therefore, no correction was made for multiple statistical tests.
Data availability
Any unpublished study data will be available for sharing with any qualified investigators after due anonymization.
Results
Group comparisons in the cortical and subcortical gray matter: MS vs HC There was no significant difference between MS and HC groups in the total cortical (1.09 ± 0.04 vs 1.11 ± 0.07, p = 0.72) and subcortical gray matter regions (0.93 ± 0.06 vs 0.88 ± 0.06, p = 0.23) ( figure 1, A and B) . However, the following cortical subregions showed increased SUVRs in MS vs HC groups ( figure 1C Group comparisons in the cortical and subcortical gray matter between SPMS, RRMS, and HC groups On univariate analysis, total subcortical gray matter SUVR (SC-SUVR) was higher in the SPMS vs RRMS (0.988 ± 0.029 vs 0.891 ± 0.053, +10.8%, p = 0.002). The effect sizes and ageadjusted p values for SPMS vs RRMS were 2.07 and 0.03 and those for SPMS vs HC were 1.87 and 0.10, respectively ( figure  1E ). On the other hand, total cortical SUVR was not significantly different among the SPMS, RRMS, and HC groups ( figure 1F ). Relationship between PET and physical disability In the MS group, there were significant correlations between the EDSS score and subcortical gray matter SUVR (r = 0.74, p = 0.005) (figure 2A) but not cortical SUVR (r = 0.05, p = 0.87). There were significant correlations between the EDSS score and SUVR in the thalamus (r = 0.83, p = 0.0008) and putamen (r = 0.71, p = 0.0089) (figures 2B and 3A). No significant correlations were seen between the EDSS score and SUVR in the caudate (r = 0.28, p = 0.37) or globus pallidus (r = 0.42, p = 0.17). On SPM analysis, age-and sex-adjusted correlations were seen in the thalamus between the EDSS score and PET uptake (p = 0.02). The peak thalamic voxels showing significant correlation with the EDSS score in the thalamus were localized to the dorsomedial nucleus ( figure 3B ).
Relationship between PET and T25FW
In the MS group, there were significant correlations between T25FW and subcortical gray matter SUVRs (r = 0.70, p = 0.01) (figure 2C) but not cortical SUVR. There was a significant correlation between T25FW and SUVR in the thalamus (r = 0.65, p = 0.02) ( figures 2D and 3A) . The correlation coefficient between T25FW and putaminal SUVR was 0.57 but did not attain statistical significance (p = 0.053) ( figure 2D ). No significant correlations were seen between T25FW and SUVR in the caudate (r = 0.44, p = 0.15) and globus pallidus (r = 0.40, p = 0.19). On SPM analysis, age-and sex-adjusted correlations were seen in the thalamus between T25FW and PET uptake (p = 0.02). The peak thalamic voxels showing significant correlation with T25FW in the thalamus were localized to the dorsomedial nucleus ( figure 3C ). On SPM analysis, peak thalamic voxels showing significant ageand sex-adjusted decreases in BPV with increasing PET uptake were localized to the pulvinar (p = 0.02) ( figure 3D ).
Discussion
The key findings of our pilot study are as follows: (1) Subcortical gray matter demonstrated higher microglial activation in patients with SPMS compared with patients with RRMS , and BPV in the thalamus. The color bars represent T-scores, and the colored highlights show the localization of peak clusters of voxels, demonstrating increases with the EDSS score and T25FW in the dorsomedial nucleus of the thalamus (orange arrows) and a decrease with BPV in the pulvinar (purple arrows). BPV = normalized brain parenchymal volume; EDSS = Expanded Disability Status Scale; HC = healthy control; RR = relapsing-remitting; SP = secondary progressive; SUVR = standardized uptake value ratios; T25FW = timed 25-foot walk.
and HCs, and this activation correlated with physical disability measures (EDSS score and T25FW) in patients with MS; (2) Thalamic and putaminal microglial activation primarily drove these findings in the subcortical gray matter, and thalamic microglial activation correlated with brain atrophy; (3) Regional cortical microglial activation in several limbic and paralimbic cortical regions (but not total cortical gray matter microglial activation) was increased in the MS group.
These PET findings underscore the role of microglial activation in progression of disease in MS with accumulation of microglial activation burden in SPMS, particularly in the subcortical gray matter. Gray matter microglial activation in MS has not been studied before using [F-18]PBR06, a longerhalf-life PET tracer. There is an urgent need to identify an imaging biomarker linked to progressive MS, and our results suggest that [F-18]PBR06 PET is a promising technique in this regard. Increased microglial activation in SPMS has been previously reported using [C-11]PK11195 in the cortical gray matter 17 and using [C-11]PBR28 in cortical and subcortical gray matter regions, 18 but both [C-11]PK11195 and [C-11] PBR28 are short half-life PET tracers, which are not easily adapted for routine clinical use.
Our study demonstrates the correlation of thalamic microglial activation with brain atrophy, EDSS score, and T25FW suggesting a central role of thalamic neuroinflammation in the pathogenesis and disease progression in MS. Extensive pathologic changes have been demonstrated in the thalamus 19 that may also be related to the high thalamic iron content. 20 Thalamic elevation of myoinositol concentration, reflecting increased glial activity, has been reported in MS using magnetic resonance spectroscopy. 21 Thalamic atrophy is known to occur throughout the course of MS at an accelerated rate, compared with HCs, 22 and microglial activation may play a causative role in its development. This aspect is a key to understanding of the mechanism of brain atrophy in MS and requires further investigation. A previous PET study has demonstrated an association of cortical thinning with thalamic TSPO binding, using a C-11 labeled tracer. 18 Progressive reductions in thalamic and putaminal T2-hypointensity, suggesting increasing iron deposition, have been associated with clinical progression in a 4-year longitudinal study of patients with MS. 23 Increased thalamic TSPO binding in patients with SPMS 24 and in a separate cohort of 8 patients with RRMS, 3 with PPMS, and 1 with SPMS 25 compared with HCs has been described using [C-11]PK11195. 24, 25 Similarly, several subcortical gray matter regions, including the thalamus and putamen, demonstrated demyelination, microglial activation, and neurodegeneration on pathologic examination of brain sections from patients with MS compared with controls. 19 We found correlation of microglial activation in the dorsomedial thalamic nucleus with increasing disability and correlation of brain atrophy with microglial activation in the pulvinar. These findings are similar to a recent report of decreased magnetic susceptibility in the pulvinar in SPMS and in the rest of thalamus including the dorsomedial nucleus in patients with RRMS. 26 Chronic microglial activation may lead to cellular injury and iron depletion from oligodendrocytes, accounting for PET findings and decreased magnetic susceptibility in these regions. 26 Cortical gray matter findings of our study are consistent with pathologic and neuroimaging data available in the literature. Extensive hippocampal demyelination accompanied by microglial activation has been demonstrated on autopsy examination of MS brains. 27 Several of these specimens demonstrated involvement of both the hippocampus and parahippocampal cortices. 27, 28 Hippocampal elevation of myoinositol concentration, reflecting increased glial activity, has been reported in MS using magnetic resonance spectroscopy. 21 Of interest, in an autopsy study of patients with SPMS, ectopic B-cell follicles were most frequently found in forebrain regions, including the temporal and cingulate cortex, and correlated with increased demyelination and parenchymal CD68 + cells in proximity to these regions. 29 Regional brain atrophy patterns have been identified, and atrophy in temporal and cingulate cortical regions has been associated with cognitive changes in MS. 30 Other PET studies using C-11-labeled radioligands have shown similar results on cross-sectional comparison. Using [C-11]PK11195, spatially heterogeneous increases in TSPO binding were demonstrated in multiple cortical brain regions, including the parahippocampal and fusiform gyri. 17 Another PET study demonstrated increased hippocampal TSPO binding in MS vs HCs that correlated with depression scores and hippocampal functional connectivity measures. 31 Of interest, the cuneus and medial-superior frontal gyrus showed reduced PET uptake in patients with MS in our study. This finding may represent a partial volume effect from severe atrophy in these regions or locally "burnt out" disease with chronic scar formation and requires further confirmation and evaluation in future studies.
The underlying mechanisms connecting cortical and subcortical microglial activation in MS are not clear. The relationship between cortical and thalamic pathology may be mediated via thalamocortical projection pathways. It is known that the "core" or C-type thalamic cells project to layer 4 of the cerebral cortex and "matrix" or M-type thalamic neurons project to the apical dendritic tufts in outermost cortical layer 1, which, in turn, is affected by the subpial gray matter lesions that are a specific aspect of MS pathology. 32 In addition, diffusion tensor fractional anisotropy values have been reported to be reduced in the cingulum, fornix, and uncinate fasciculus, along with thalamic and hippocampal atrophy, suggesting disruption of hippocampal-thalamic-prefrontal connections in patients with RRMS. 33 Microglial activation may be a cause or effect of neurodegeneration, 34 and the cross-sectional nature of our study cannot definitively answer that question. Mechanistically, activated microglia can cause ongoing injury in non-antigen-dependent manner, mediated via the production of cytokines, glutamate, oxygen radicals, nitric oxide, matrix proteases, and putative proapoptotic signals. 35, 36 It has been shown that microglial activation correlates with neurofilament positive swellings at terminal ends of transected axons and dendrites in demyelinating lesions. In addition, the pattern of microglial targeting of neurons suggests neuronal damage via a process of synaptic stripping. 35, 37 Neuronal apoptosis and atrophy may result from axonal transection and other neuronal or axonal damage. In cortical gray matter lesions, there microglia are not abundant, but they are highly activated. 38 Recently, CCR2+ monocytes were found to be necessary for the development of both type 2 intracortical and type 3 subpial gray matter lesions. 39 The limitations of our pilot study include its small sample size and cross-sectional design. We did not correct for multiple comparisons while assessing statistical significance, and hence, our findings represent trends that require further confirmation. Increased microglial activation has been reported in the caudate on histopathologic examination but was not detected on PET in our study, which may be due to sample size or partial volume effects diluting the PET signal in an atrophied caudate nucleus. However, this is the first study of [F-18]PBR06 PET, assessing gray matter changes in MS, demonstrating potential value of this technique. The practical advantages of this longer half-life tracer have implications for its potential clinical use in the long term, and hence, larger studies with longitudinal design are needed to confirm and extend the findings of our pilot study.
This study suggests that [F-18]PBR06 PET detects widespread abnormal brain microglial activation in the cerebral gray matter in MS, and increased activation in subcortical gray matter regions is associated with brain atrophy and physical disability. Further studies of [F-18] PBR06 PET in MS are warranted.
